TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02604563

Intervention type: OTHER
Intervention: MOS Social Activity Survey
Description: * 4 items about social activity~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: MOS Social Activity Survey
Description: * 4 items about social activity~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: MOS Social Activity Survey
Description: * 4 items about social activity~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Unintentional Weight Loss
Description: * 2 items about nutrition~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Unintentional Weight Loss
Description: * 2 items about nutrition~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Unintentional Weight Loss
Description: * 2 items about nutrition~* Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Peripheral Blood Draw
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Peripheral Blood Draw
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Peripheral Blood Draw
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Buccal Swab
Description: * Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Buccal Swab
Description: * Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death

Intervention type: GENETIC
Intervention: Buccal Swab
Description: * Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)~* Baseline and no more frequently than every 6 months until death
Study: NCT02513407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Attend healthy nutritional education session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Attend healthy nutritional education session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend EML educational session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Attend exercise educational session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Intervention
Description: Receive fitness tracker

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02517034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment
Description: Follow geriatric assessment-driven treatment plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01630330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Description: Atrial Fibrillation Ablation with SmartTouch catheter
Study: NCT02604563

Intervention type: OTHER
Intervention: Heart Health and Smoking History from BRFSS questionnaire
Description: * 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Heart Health and Smoking History from BRFSS questionnaire
Description: * 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death
Study: NCT00102622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
Study: NCT03591042

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cervical length screening
Description: transvaginal ultrasound cervical length
Study: NCT01630330

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Atrial Fibrillation Ablation with SmartTouch catheter
Study: NCT02804074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimization of antihypertensive treatment based on office BP
Description: Optimization of antihypertensive treatment based on office BP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimization of antihypertensive treatment based on 24-hour ABPM
Description: Optimization of antihypertensive treatment based on 24-hour ABPM
Study: NCT03998956

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI
Description: Circumferential PV isolation only
Study: NCT02517034

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03090646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Up to three gift cards to a major online retailer.
Study: NCT02604563

Intervention type: OTHER
Intervention: Heart Health and Smoking History from BRFSS questionnaire
Description: * 7 items about heart health and smoking history~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Gait Speed
Description: * Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Gait Speed
Description: * Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Gait Speed
Description: * Research coordinator will test gait speed~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Grip Strength
Description: * Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Grip Strength
Description: * Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Grip Strength
Description: * Research coordinator will test grip strength~* Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Height and Weight measurements
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Height and Weight measurements
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Height and Weight measurements
Description: -Baseline and no more frequently than every 6 months until death
Study: NCT00004888

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03340337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo-Russian
Description: Subjects will receive Neo-Russian electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aussie
Description: Subjects will receive Aussie electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RBS
Description: Subjects will receive RBS electrical stimulation with three reps (5 sec work x 120 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured. They will be asked how uncomfortable the stimulation was, using Visual Analogue Scale (VAS).~One week later, subjects will receive a fatigue protocol that consists in 21 reps (5 sec work x 5 sec rest), and the Maximal Electrical Induced Contraction (MEIC) will be measured for each contraction.
Study: NCT02579265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid 20% (investigational lipid for parenteral nutrition)
Description: Dose: The targeted maximal dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.~Smoflipid 20% will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.~Smoflipid 20% will be infused into a central or a peripheral vein.
Study: NCT02088801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airtraq, blade without channel for tracheal tube intubation
Description: Intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KingVision , blade without channel for tracheal tube intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A.P. Advance, blade without channel for tracheal tube intubation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Study: NCT02043704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen
Description: Details covered in arm description.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV Acetaminophen
Description: Details covered in arm description.
Study: NCT02604563

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: OTHER
Intervention: Blood pressure measurement
Description: -Baseline and no more frequently than every 6 months until death

Intervention type: PROCEDURE
Intervention: Optional bone marrow biopsy
Description: -1 optional bone marrow biopsy

Intervention type: PROCEDURE
Intervention: Optional bone marrow biopsy
Description: -1 optional bone marrow biopsy

Intervention type: PROCEDURE
Intervention: Blood draw for trauma measurements
Description: -For Arm E only
Study: NCT04558372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants breath through non-rebreathing mask until the reservoir bag is full. The reservoir bag is connected to Hepa-filter at one side, and another side of Hepa-filter is connected to the electronic-nose (Genosvid) device.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaled breath sampling
Description: The participants breath normally using a mask for 2 times then they are asked to inhale and exhale in a forced expiratory volume through an e-nose tube connected to the Hepa-filter at the inlet.
Study: NCT01403415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV
Study: NCT03998956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI+BOX
Description: Circumferential PV and BOX isolation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPVI+BOX+SUB
Description: Atrial substrate ablation apart from circumferential PV and BOX isolation
Study: NCT02421289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: There will be adjusted dose of efavirenz in CYP2B6 guide group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CYP450 2B6
Description: All patients will be monitored drug level which should be in therapeutic level.
Study: NCT01403415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04007445

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Formally Directed Group (Exercise Group)
Description: This group will receive a 12-week exercise intervention that will educate and support the person's ability to exercise. Working with a trainer, the participant will attend a 12-week (3 x week) exercise program that has been personalized to their goals. Each session will include warm-up, stretching, cardiovascular exercises, strength exercises, and cool-down. Each session will be 1-2 hours in duration. The participants may wear accelerometers and heart rate monitors to help determine the level of intensity of the exercises, as they should be performing at least 150 minutes of moderate to vigorous exercise each week. By the end of the 12-week program, the goal is for participants to guide their own exercise regimens.
Study: NCT01403415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT02560012

Intervention type: DRUG
Group type: OTHER
Intervention: Sunitinib
Description: One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off

Intervention type: DRUG
Group type: OTHER
Intervention: Temsirolimus
Description: 25 mg by an IV infusion over 30-60 minutes, once a week
Study: NCT04007445

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Self-Directed Group (Control Group)
Description: This group will receive a 1-hour education session during which they will learn about the National Council on Health, Physical Activity and Disability (NCHPAD) website, an information and resource center on health promotion for people with disabilities. During the session participants will be given an overview of the website and asked to find three resources they find of interest. Their strength and fitness will also be assessed by completing a 1-rep max test. The participants will then be asked to maintain their regular physical activity for the next 12 weeks and complete a weekly physical activity log to track their exercise participation. A staff member will phone each person every week for the 12-week period and have the participant report his or her physical activity during the week.
Study: NCT04086342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHI-902
Description: A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.
Study: NCT00617994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 1.5% cream BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 1.5% cream BID for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib 1.5% cream BID for 28 days
Study: NCT05896605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Description: Before medication, TPMT activity was normal, and AZA was started at small doses and added every two weeks after no AEs, namely 50 mg qd for two weeks, 50mg bid for two weeks, and maintained at 50mg tid.
Study: NCT01848925

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SANGUINATE™
Description: 40 mg/mL intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Standard of care for Sickle Cell treatment, 15 mg/kg.
Study: NCT01144429

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergoid, allergenic extract of 100% Birch
Description: Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergoid, allergenic extract of 100% Birch
Description: Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergoid, allergenic extract of 100% Birch
Description: Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergoid, allergenic extract of 100% Birch
Description: Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
Study: NCT02928055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Stimulation
Description: The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.